Revenue
2010
2011
DAXOR CORP (DXR)
Price—Loading quote
Net income
2010
2011
Free cash flow
2010
2011
Total cash / debt
CashTotal debt
2009
2010
2011
Financial statements
| 2011 | 2010 | |
|---|---|---|
| Revenue | $1.4M | $1.6M |
| Gross profit | $793,834 | $851,607 |
| Research & development | $2.7M | $3.0M |
| Operating expenses | $6.6M | $6.5M |
| Operating income | −$5.8M | −$5.7M |
| Net income | −$7.2M | $5.0M |
| Basic EPSper diluted share | -$1.70 | $1.17 |
| Diluted EPSper diluted share | -$1.70 | $1.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 8, 2026Form 4 | Feldschuh Michael RichardChief Executive Officer | BuyDaxor Common Stock | 1.0K | $9.07 | $9.1K | 213.7K |
| Mar 31, 2026Form 4 | Michel Robert JChief Financial Officer | BuyDaxor Common Stock | 1.0K | $9.90 | $9.9K | 21.1K |
| Mar 20, 2026Form 4 | Jefferies JohnChief Medical Officer | BuyDaxor Common Stock | 2.3K | $0.00 | $0.00 | 23.6K |
| Mar 20, 2026Form 4 | Jefferies JohnChief Medical Officer | BuyDaxor Common Stock | 3.7K | $0.00 | $0.00 | 21.3K |
| Dec 9, 2025Form 4 | Michel Robert JChief Financial Officer | BuyDaxor Common Stock | 3.0K | $0.00 | $0.00 | 20.1K |